Artikelen door HollandBIO

,

Facio therapies haalt 8 miljoen euro op in financieringsronde

Vorige week maakte Facio Therapies bekend een succesvolle financieringsronde afgesloten te hebben. Hiermee heeft het bedrijf 8 miljoen euro opgehaald om de al eerder aangekondigde in vivo proof of principle studies verder uit te breiden. Het ultieme doel is om zo uiteindelijk een FSHD-therapie te ontwikkelen. Het volledige nieuwsbericht lees je hier. Het rondkrijgen van […]

, ,

Staatssecretaris Blokhuis in actie voor het belang van vaccineren

Het is Staatssecretaris Blokhuis menens: om de dalende vaccinatiegraad een halt toe te roepen zet hij in op meer zichtbaarheid voor het belang van vaccins en een vergroot draagvlak en vaccinatiebereidheid onder de bevolking. In een brief aan de Tweede Kamer, “Verder met vaccineren”, licht hij zijn aanpak nader toe. De doortastendheid van Blokhuis weten […]

IBDream wil 5.000 IBD-patiënten gaan bedienen in 2020

Vijf Nederlandse ziekenhuizen hebben de handen ineen geslagen om optimale zorg te leveren aan mensen die lijden aan Inflammatory Bowel Disease (IBD). IBDream, een persoonlijk online dossier, dat tevens dient als onderzoeksregister, wordt hiervoor ingezet. IBDream bedient nu 2.000 patiënten. De ambitie is om in 2020, door meer ziekenhuizen te laten aansluiten, maar liefst 5.000 […]

Facio raises €8M in equity financing

Facio Therapies announced today that it had successfully completed an equity financing round with proceeds of €8M (approximately A$12.5M; C$12M; US$9M). FSHD Spain and 30 other members of the FSHD community newly invested alongside existing investors, including Facio’s drug discovery partner, Evotec. Facio will use these funds to expand its recently announced in vivoproof of principle […]

DCprime: first patient dosed in phase 2 study

DCprime, a clinical stage biotechnology company focused on cancer immunotherapies, announces that the first patient has been dosed with DCP-001 in a phase 2 study, called ADVANCE-II. Patients with Acute Myeloid Leukemia (AML) in complete remission after induction therapy but with persistence of measurable residual disease (MRD) will be included in this multi-centre study. Effects […]

uniQure Announces Initial Topline Data

uniQure, a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced initial clinical data in patients treated in the Company’s Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant, for the treatment of patients with severe and moderately severe hemophilia B. […]

ttopstart joins PNO Group

ttopstart and PNO will join forces in their ambition to become Europe’s leading consultancy in strategy and funding services in life sciences and health. Together, ttopstart-PNO will now have 50 life sciences professionals located in 6 European countries. ttopstart was founded in 2009 as a university spin-off from the VU University in Amsterdam. Since then, the […]

,

Cargill and Royal DSM to establish joint venture Avansya: to bring zero-calorie, cost-effective sweeteners to market faster

Avansya venture to help food and beverage producers deliver the products and brands consumers love, with significantly reduced calories As food and beverage producers look to significantly reduce calories in their offerings to consumers, they are in need of non-artificial, zero-calorie, great-tasting sweetener options. Today,Cargill and Royal DSM, a global science-based company in Nutrition, Health and […]

Fruitful BIO-Europe for Dutch Biotech Community

Last week, more than 4300 attendees from all over the world visited BIO-Europe in Copenhagen, the largest European partnering conference for biotech and biopharma. The conference welcomed a strong delegation of over 150 Dutch biotech entrepreneurs. The well-attended Health~Holland Pavilion served as the central information point for international visitors with questions regarding the Dutch business […]